1461087701-ac80aa95-f389-4340-98e3-ed008d3403ea

1. A recombinant virus comprising an adenovirus capsid, which capsid comprises an adenovirus C68 penton of SEQ ID NO:12, said capsid encapsidating a molecule for delivery to a target cell, wherein the molecule comprises an adenovirus 5\u2032 inverted terminal repeat sequence (ITR), a minigene, and an adenovirus 3\u2032 ITR sequence.
2. The recombinant adenovirus according to claim 1, wherein the adenovirus ITRs are from a serotype heterologous to C68.
3. The recombinant virus according to claim 1, wherein the capsid further comprises an adenovirus capsid protein heterologous to C68.
4. The recombinant virus according to claim 1, wherein the capsid further comprises a modified adenovirus C68 fiber protein or a fragment thereof comprising at least 8 amino acids.
5. The recombinant virus according to claim 4, wherein the fiber protein fragment is the knob having the sequence of about amino acid 247 to about amino acid 425 of SEQ ID NO: 27.
6. The recombinant virus according to claim 4, wherein the modified adenovirus C68 fiber protein comprises the adenovirus C68 fiber protein with a fiber knob sequence from another adenovirus inserted in the region of about amino acid 247 to about amino acid 425 of SEQ ID NO: 27.
7. The recombinant virus according to claim 4, wherein the modified adenovirus C68 fiber protein fragment is selected of the group consisting of SEQ ID NO: 27 having a 50 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 100 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 150 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 200 amino acid N-terminal or C-terminal truncation, and a fragment of the fiber protein having the sequence of amino acids 247 to 425 of SEQ ID NO:27.
8. A recombinant virus comprising an adenovirus capsid, which capsid comprises one or more fragments of the C68 penton of SEQ ID NO:12 fused to a heterologous adenovirus capsid protein, said capsid encapsidating a molecule for delivery to a target cell, wherein the molecule comprises an adenovirus 5\u2032 inverted terminal repeat sequence (ITRs), a minigene, and an adenovirus 3\u2032 ITR,
said fragment selected from the group consisting of: SEQ ID NO:12 having a 50 amino acid N-terminal or C-terminal truncation; SEQ ID NO:12 having a 100 amino acid N-terminal or C-terminal truncation; SEQ ID NO:12 having a 150 amino acid N-terminal or C-terminal truncation; SEQ ID NO:12 having a 200 amino acid N-terminal or C-terminal truncation.
9. The recombinant adenovirus according to claim 8, wherein the adenovirus ITRs are from a serotype heterologous to C68.
10. The recombinant virus according to claim 8, wherein the capsid further comprises an adenovirus capsid protein heterologous to C68.
11. The recombinant virus according to claim 8, wherein the capsid further comprises a modified adenovirus C68 fiber protein or a fragment thereof comprising at least 8 amino acids.
12. The recombinant virus according to claim 11, wherein the fiber protein fragment is the knob having the sequence of about amino acid 247 to about amino acid 425 of SEQ ID NO: 27.
13. The recombinant virus according to claim 11, wherein the modified adenovirus C68 fiber protein comprises the adenovirus C68 fiber protein with a fiber knob sequence from another adenovirus inserted in the region of about amino acid 247 to about amino acid 425 of SEQ ID NO: 27.
14. The recombinant virus according to claim 11, wherein the modified adenovirus C68 fiber protein fragment is selected of the group consisting of SEQ ID NO: 27 having a 50 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 100 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 150 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 200 amino acid N-terminal or C-terminal truncation, and a fragment of the fiber protein having the sequence of amino acids 247 to 425 of SEQ ID NO:27.
15. A recombinant virus comprising an adenovirus capsid, which capsid comprises an adenovirus C68 fiber of SEQ ID NO:27 and an adenovirus capsid protein from a different adenovirus, said capsid encapsidating a molecule for delivery to a target cell, wherein the molecule comprises an adenovirus 5\u2032 inverted terminal repeat sequence (ITRs), a minigene, and an adenovirus 3\u2032 ITR.
16. The recombinant adenovirus according to claim 15, wherein the adenovirus ITRs are from a serotype heterologous to C68.
17. The recombinant virus according to claim 15, wherein the capsid further comprises an adenovirus capsid protein heterologous to C68.
18. The recombinant virus according to claim 15, wherein the capsid further comprises a modified adenovirus C68 penton protein or a fragment thereof comprising at least 8 amino acids.
19. The recombinant virus according to claim 15, wherein the modified adenovirus C68 penton protein fragment is selected of the group consisting of SEQ ID NO:12 having a 50 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 12 having a 100 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 12 having a 150 amino acid N-terminal or C-terminal truncation; and SEQ ID NO: 12 having a 200 amino acid N-terminal or C-terminal truncation.
20. A recombinant virus comprising an adenovirus capsid, which capsid comprises one or more fragments of the C68 fiber of SEQ ID NO: 27 fused to a heterologous adenovirus capsid protein, said capsid encapsidating a molecule for delivery to a target cell, wherein the molecule comprises an adenovirus 5\u2032 inverted terminal repeat sequence (ITRs), a minigene, and an adenovirus 3\u2032 ITR,
said fragment selected from the group consisting of: SEQ ID NO: 27 having a 50 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 100 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 150 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 27 having a 200 amino acid N-terminal or C-terminal truncation, and a fragment of the fiber protein having the sequence of amino acids 247 to 425 of SEQ ID NO:27.
21. The recombinant adenovirus according to claim 20, wherein the adenovirus ITRs are from a serotype heterologous to C68.
22. The recombinant virus according to claim 20, wherein the capsid further comprises an adenovirus capsid protein heterologous to C68.
23. The recombinant virus according to claim 20, wherein the capsid further comprises a modified adenovirus C68 penton protein or a fragment thereof comprising at least 8 amino acids.
24. The recombinant virus according to claim 20, wherein the modified adenovirus C68 penton protein fragment is selected of the group consisting of SEQ ID NO: 12 having a 50 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 12 having a 100 amino acid N-terminal or C-terminal truncation; SEQ ID NO: 12 having a 150 amino acid N-terminal or C-terminal truncation; and SEQ ID NO: 12 having a 200 amino acid N-terminal or C-terminal truncation.
25. A pharmaceutical composition comprising a physiologically acceptable carrier and a recombinant virus according to claim 1.
26. A pharmaceutical composition comprising a physiologically acceptable carrier and a recombinant virus according to claim 8.
27. A pharmaceutical composition comprising a physiologically acceptable carrier and a recombinant virus according to claim 15.
28. A pharmaceutical composition comprising a physiologically acceptable carrier and a recombinant virus according to claim 20.
29. A method for rapid screening of recombinant constructs comprising the steps of:
(a) providing a first parent construct having a green fluorescent protein (GFP), operably linked to regulatory sequences which permit its expression in a host cell, downstream of the portion of the first parent construct to be in the recombinant construct;
(b) providing a second parent construct having a GFP operably linked to regulatory sequences which permit its expression in a host cell upstream of the portion of the second parent construct to be in the recombinant construct;
(c) culturing a selected host cell with the first parent construct and second parent construct under conditions which permits them to homologously recombine; and
(d) screening for the absence expression of GFP expression, which indicates the presence of the recombinant construct.
30. The method according to claim 29, wherein the regulatory sequence comprises the prokaryotic promoter from lacZ.
31. The method according to claim 29, wherein the first parent construct is a plasmid.
32. The method according to claim 29, wherein the second parent constructs is a plasmid.
33. The method according to claim 29, wherein the first parent construct and the second parent construct are provided by co-transfection into the cell.
34. The method according to claim 29, wherein one of the first parent construct or the second parent construct is stably contained within the host cell.
35. A host cell comprising:
(a) a first parent construct having a green fluorescent protein (GFP), operably linked to regulatory sequences which permit its expression in a host cell, downstream of the portion of the first parent construct to be in the recombinant construct; and
(b) a second parent construct having a GFP operably linked to regulatory sequences which permit its expression in a host cell upstream of the portion of the second parent construct to be in the recombinant construct.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A nonvolatile memory device comprising:
a substrate;
a vertical channel layer projecting from a surface of the substrate, in a direction perpendicular to the surface;
a tunnel dielectric layer surrounding the vertical channel layer;
a plurality of interlayer dielectric layers and a plurality of control gate electrodes alternately formed along the vertical channel layer;
floating gate electrodes interposed between the tunnel dielectric layer and the plurality of control gate electrodes, the floating gate electrodes comprising a metal-semiconductor compound; and
a charge blocking layer interposed between each of the plurality of control gate electrodes and each of the plurality of floating gate electrodes,
wherein the floating gate electrodes are protruded beyond side surfaces of the plurality of interlayer dielectric layers, toward the vertical channel layer.
2. The nonvolatile memory device according to claim 1, wherein the metal-semiconductor compound comprises a metal silicide or a metal germanide.
3. The nonvolatile memory device according to claim 1, wherein portions of the tunnel dielectric layer are interposed between the floating gate electrodes and the vertical channel layer, and where other portions of the tunnel dielectric layer are interposed between the plurality of interlayer dielectric layers and the vertical channel layer, and
where the portions of the tunnel dielectric layer that are interposed between the floating gate electrodes and the vertical channel layer are thinner than the other portions of the tunnel dielectric layer that are interposed between the plurality of interlayer dielectric layers and the vertical channel layer.
4. The nonvolatile memory device according to claim 1, wherein a width, measured in a direction parallel to the substrate, of each of the floating gate electrodes is smaller than a width, measured in the direction parallel to the substrate, of each of the plurality of control gate electrodes.
5. The nonvolatile memory device according to claim 1, wherein the charge blocking layer is interposed between each of the plurality of control gate electrodes and each of the plurality of interlayer dielectric layers.

1461087691-1efe54ec-6dfd-41a7-990b-19b9a426eacf

1. A method for multiplexing control signals, the method comprising:
coding control signals for at least one user signals to correspond to a structure of a transmission block for the control signals among one or more dedicated resource block;
multiplexing the control signals for the at least one user signals in the dedicated resource block; and
transmitting the control signals,
wherein the dedicated resource block is allocated for transmitting the control signals separately from data signals among a plurality of transmission resource blocks.
2. The method of claim 1, wherein the control signals are multiplexed by using different subcarriers of the dedicated resource block to each of the control signals.
3. The method of claim 1, wherein the control signals are multiplexed by multiplying by different sequences to each of the control signals.
4. The method of claim 1, wherein pilot signals are multiplexed in the dedicated resource block.
5. The method of claim 4, wherein a structure of the transmission block for the control signals is the same as that of a transmission block for the pilot signals.
6. The method of claim 5, the pilot signals are multiplexed in a same manner with corresponding control signals.
7. The method of claim 4, wherein a structure of the transmission block for the control signals is different from that of a transmission block for the pilot signals.
8. The method of claim 7, the pilot signals are multiplexed in a different manner with corresponding control signals.
9. The method of claim 7, wherein the pilot signals are allocated to different transmission blocks for the pilot signals to each of corresponding control signals.
10. The method of claim 7, wherein the pilot signals is a sequence having orthogonality.
11. The method of claim 10, wherein the sequence is a CAZAC (Constant Amplitude Zero AutoCorrelation) sequence.
12. The method of claim 7, wherein the pilot signals is coded by using code having orthogonality.
13. The method of claim 12, wherein the code having orthogonality is at least one of hadamard code and simplex code.
14. The method of claim 3, wherein the sequences are generated through at least one of a method for constituting sequences differently and a method for performing cyclic shift to the sequence.
15. The method of claim 14, wherein the sequences constituted differently are allocated to each cell, and sequences generated by performing cyclic shift to the sequence are allocated to each user of the each cell.
16. The method of claim 14, wherein the sequences allocated to neighboring cells are cyclic shifted with different pattern.
17. The method of claim 3, wherein the sequences are multiplied by the control signals in at least one direction of a time axis and a frequency axis of the dedicated resource block.
18. The method of claim 3, wherein a length of the sequences is determined by the number of subcarriers of the dedicated resource block if the sequences are multiplied by the control signals on a frequency axis.
19. The method of claim 1, wherein the control signals are identified for each user.
20. The method of claim 1, wherein the control signals include at least one of channel quality information (CQI), ACKNACK signals, rank indicator (RI), and precoding matrix indicator (PMI).

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A coordination complex, comprising:
a first biologically active moiety;
a second biologically active moiety; and
a metal,
wherein the first biologically active moiety and second biologically active moiety are each bound to the metal by at least one binding site,
wherein the first biologically active moiety and second biologically active moiety are different; and
wherein the first biologically active moiety and the second biologically active moiety both have a biological effect on a target tissue.
2. The coordination complex of claim 1, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on a same target tissue.
3. The coordination complex of claim 1, wherein the first biologically active moiety and the second biologically active moiety have a biological effect on a tissue associated with the same disease state.
4. The coordination complex of claim 1, wherein the first biologically active moiety and the second biologically active moiety have a biological effect on a same target tissue associated with a disease state.
5. The coordination complex of claim 3, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on receptors on the tissue associated with the same disease state.
6. The coordination complex of claim 4, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on receptors on the same tissue associated with a same disease state.
7. The coordination complex of claim 1, wherein the first biologically active moiety and the second biologically active moiety have more than one binding site that is capable of binding the metal.
8. The coordination complex of claim 1, wherein the binding site comprises a donor atom.
9. The coordination complex of claim 1, wherein the first biologically active moiety, second biologically active moiety, and the metal form a polynuclear complex.
10. The coordination complex of claim 1, wherein the metal is a transition metal.
11. The coordination complex of claim 1, wherein the metal is a s-block metal.
12. The coordination complex of claim 1, wherein the metal is a p-block metal.
13. The coordination complex of claim 1, wherein the metal is a d-block metal.
14. The coordination complex of claim 1, wherein the metal is an inner transition metal of the lanthanide and actinide series.
15. The coordination complex of claim 1, wherein the metal is selected from the group consisting of magnesium, calcium, iron, cobalt, nickel, copper, zinc, palladium, platinum, ruthenium, rhodium, aluminum, cadmium, vanadium, chromium, strontium, and tin.
16. The coordination complex of claim 1, wherein the first biologically active moiety and the second biologically active moiety are capable of potentiating each other.
17. The coordination complex of claim 1, further comprising a component selected from the group consisting of an amino acid, a lipid, a carbohydrate, a nucleic acid, and a peptide.
18. The coordination complex of claim 1, wherein the metal has a biological effect on a target tissue.
19. The coordination complex of claim 1, wherein the metal potentiates the biological effect of at least one of the first biological moiety and the second biological moiety.
20. A method for enhancing the biological effect of biologically active moieties, comprising:
forming a coordination complex comprising a first biologically active moiety, a second biologically active moiety, and a metal,
wherein the first biologically active moiety and the second biologically active moiety are each bound to the metal by at least one binding site,
wherein the first biologically active moiety and the second biologically active moiety are different, and
wherein the first biologically active moiety and the second biologically active moiety both have a biological effect on a target tissue.
21. The method of claim 20, wherein the forming of the coordination complex enhances the pharmacodynamic properties through synergistic pharmacokinetic application of the first biologically active moiety and the second biologically active moiety.
22. A method of treatment, comprising:
administering a coordination complex comprising at least a first biologically active moiety, a second biologically active moiety, and a metal,
wherein the first biologically active moiety and the second biologically active moiety both have a biological effect on a target tissue.
23. The coordination complex of claim 22, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on a same target tissue.
24. The coordination complex of claim 22, wherein the first biologically active moiety and the second biologically active moiety have a biological effect on a tissue associated with the same disease state.
25. The coordination complex of claim 22, wherein the first biologically active moiety and the second biologically active moiety have a biological effect on a same target tissue associated with a disease state.
26. The coordination complex of claim 24, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on receptors on the tissue associated with the same disease state.
27. The coordination complex of claim 25, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on receptors on the same tissue associated with a same disease state.
28. The method of claim 22, wherein at least the first biologically active moiety potentiates the biological effect of the second biologically active moiety.